Eli Lilly and Co (LLY)

Industry Drug Manufacturers - General

This stock can be held in an Investment ISA and an Investment Account
Sell

$748.20

Buy

$751.00

arrow-up$25.60 (+3.50%)

Eli Lilly and Co is a pharmaceutical company with a focus on neuroscience, endocrinology, oncology, and immunology. It discovers, develops, manufactures, and sells human pharmaceutical products and animal health products.
Prices updated at 17 May 2025, 00:59 EDT
| Prices minimum 15 mins delay
|
Prices in USD

Income statement

20172018201920202021202220232024
19,974m21,493m22,320m24,540m28,318m28,541m34,124m45,043m
15,526m16,812m17,598m19,057m21,006m21,912m27,042m36,624m
4,250m6,026m5,999m7,211m7,933m8,653m10,787m17,502m
21.2828.0426.8829.3828.0130.3231.6138.86
-204m3,232m8,318m6,194m5,582m6,245m5,240m10,590m
4,097m5,532m6,899m8,913m8,043m8,661m8,568m15,228m
Sales, General and administrative6,180m5,735m6,004m5,869m6,142m6,068m6,941m8,132m
Interest expenses225m243m401m360m340m332m486m781m
Provision for income taxes2,391m530m628m1,036m574m562m1,314m2,090m
Operating expenses11,276m10,786m11,599m11,846m13,073m13,258m16,255m19,123m
Income before taxes2,305m3,680m5,266m7,230m6,156m6,806m6,555m12,680m
Net income available to common shareholders-204m3,232m8,318m6,194m5,582m6,245m5,240m10,590m
-0.193.148.936.826.156.935.8211.76
Net interest income-59m-83m-320m-327m-314m-269m-312m-605m
Advertising and promotion--------
Net investment income, net--------
Realised capital gains (losses), net--------
Total benefits, claims and expenses--------
Earnings per share (diluted)-0.193.138.896.796.126.95.811.71
Free cash flow per share3.5362.8252.77615.60035.06485.8809-0.1825-2.5162
Book value/share13.536512.3713.53255.04598.13410.598112.475715.8656
Debt equity ratio0.8575160.9356685.300512.9400521.7091051.3838291.7007962.010069

Balance sheet

20172018201920202021202220232024
Current assets19,202m20,550m13,710m17,462m18,452m18,035m25,727m32,740m
Current liabilities14,536m11,888m11,775m12,482m15,053m17,138m27,293m28,377m
Total capital21,533m21,468m16,425m22,228m24,326m25,387m29,093m42,719m
Total debt13,647m12,771m15,804m16,595m16,885m16,239m25,225m33,644m
Total equity11,592m9,829m2,607m5,642m8,979m10,650m10,772m14,192m
Total non current liabilities--------
Loans9,941m11,640m13,818m16,587m15,346m14,738m18,321m28,527m
Total assets44,981m43,908m39,286m46,633m48,806m49,490m64,006m78,715m
Total liabilities--------
Cash and cash equivalents6,536m7,998m2,338m3,657m3,819m2,067m2,819m3,268m
Common stock1,100m1,057m958m957m954m950m899m898m

Cash flow

20172018201920202021202220232024
Cash at beginning of period4,582m6,536m7,998m2,338m3,657m3,819m2,067m2,819m
Cash dividends paid-2,192m-2,312m-2,410m-2,687m-3,087m-3,536m-4,069m-4,680m
3,452m2,506m3,483m4,471m5,388m4,600m-3,152m414m
Investments (gains) losses-3,784m1,906m-8,083m-2,259m-2,762m-3,262m-7,153m-9,301m
6,536m7,998m2,338m3,657m3,819m2,067m2,819m3,268m
Net income--------
5,616m5,525m4,837m6,500m7,261m7,084m4,240m8,818m
-2,164m-3,018m-1,353m-2,029m-1,873m-2,484m-7,392m-8,404m
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.